Quisinostat Hydrochloride

盐酸奎斯诺

Report date: 2025/06/03 17:34:11
NME

Base Information

Drug NameQuisinostat Hydrochloride
Drug Alias Name盐酸奎诺司他quisinostatum奎诺司他盐酸盐JNJ-26481585-AACJNJ-26481585 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistone deacetylase 1 inhibitors
TargetsHistone deacetylase 1
Therapy Area/IndicationsUveal melanomaMyelodysplastic SyndromesCarcinoma, Non-Small-Cell Lung +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPortugalRussian Federation +[8] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesJohnson & Johnson Innovative MedicineJohnson & Johnson
China Registration ClassN/A

Develop Information

Active CompaniesIvy Brain Tumor CenterNanjing Advanced Academy of Life and HealthUniversity Of Miami
Inactive CompaniesJanssen Research & Development LlcJohnson & Johnson Pharmaceutical Research & Development LLCJanssen Pharmaceutical Nv
Active IndicationsUveal melanomaGlioblastomaMalaria
Inactive IndicationsMyelodysplastic SyndromesCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[8] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG